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Abstract
Background: Nitric oxide (NO) is a messenger implicated in the destruction and inflammation of joint tissues.
Cartilage and synovial membrane from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) have high
levels of NO. NO is known to modulate various cellular pathways and, thus, inhibit the activity of the mitochondrial
respiratory chain (MRC) of chondrocytes and induce the generation of reactive oxygen species (ROS) and cell death
in multiple cell types. For these reasons, and because of the importance of the synovial membrane in
development of OA pathology, we investigated the effects of NO on survival, mitochondrial function, and activity
of fibroblastic human OA synovial cells.
Methods: Human OA synovia were obtained from eight patients undergoing hip joint replacement. Sodium
nitroprusside (SNP) was used as a NO donor compound and cell viability was evaluated by MTT assays.
Mitochondrial function was evaluated by analyzing the mitochondrial membrane potential (Δψm) with flow
cytometry using the fluorofore DePsipher. ATP levels were measured by luminescence assays, and the activities of
the respiratory chain complexes (complex I: NADH CoQ1 reductase, complex II: succinate dehydrogenase, complex
III: ubiquinol-cytochrome c reductase, complex IV: cytochrome c oxidase) and citrate synthase (CS) were measured
by enzymatic assay. Protein expression analyses were performed by western blot.
Results: SNP at a concentration of 0.5 mM induced cell death, shown by the MTT method at different time points.
The percentages of viable cells at 24, 48 and 72 hours were 86.11 ± 4.9%, 74.31 ± 3.35%, and 43.88 ± 1.43%,
respectively, compared to the basal level of 100% (*p < 0.05). SNP at 0.5 mM induced depolarization of the
mitochondrial membrane at 12 hours with a decrease in the ratio of polarized cells (basal = 2.48 ± 0.28; SNP 0.5
mM = 1.57 ± 0.11; *p < 0.01). The time course analyses of treatment with SNP at 0.5 mM demonstrated that
treatment reliably and significantly reduced intracellular ATP production (68.34 ± 14.3% vs. basal = 100% at 6 hours;
*p < 0.05). The analysis of the MRC at 48 hours showed that SNP at 0.5 mM increased the activity of complexes I
(basal = 36.47 ± 3.92 mol/min/mg protein, SNP 0.5 mM = 58.08 ± 6.46 mol/min/mg protein; *p < 0.05) and III
(basal = 63.87 ± 6.93 mol/min/mg protein, SNP 0.5 mM = 109.15 ± 30.37 mol/min/mg protein; *p < 0.05) but
reduced CS activity (basal = 105.06 ± 10.72 mol/min/mg protein, SNP at 0.5 mM = 66.88 ± 6.08 mol/min/mg
protein.; *p < 0.05), indicating a decrease in mitochondrial mass. Finally, SNP regulated the expression of proteins
related to the cellular cycle; the NO donor decreased bcl-2, mcl-1 and procaspase-3 protein expression.
Conclusions: This study suggests that NO reduces the survival of OA synoviocytes by regulating mitochondrial
functionality, as well as the proteins controlling the cell cycle.
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Background
Osteoarthritis (OA) is a common cartilage and joint dis-
ease related to age and characterized by a reduction in
the number of chondrocytes, loss of the extracellular
matrix, and synovial inflammation [1,2]. It has been
shown that in the last phases of OA the synovial mem-
brane plays an important role in the progression of the
pathology. This tissue synthesizes inflammation media-
tors, such as cytokines [interleukin-1a (IL-1a), IL-1b
and tumor necrosis factor-a (TNF-a)], proteases (col-
lagenases and the aggrecanases), lipidic mediators [pros-
taglandin E2 (PGE2) and leukotriene B4 (LTB4)], and
nitric oxide (NO) [3].
NO is a small hydrophobic molecule with chemical
properties that make it uniquely suitable as both an
intra- and intercellular messenger [4]. NO is produced in
high quantities by the synovium and chondrocytes in
rheumatoid pathologies, such as OA and rheumatoid
arthritis (RA) [5-8]. Recent studies show that NO influ-
ences mitochondria, particularly in the activity of the
mitochondrial respiratory chain (MRC). NO has many
consequences on cell function, including cell death
[9,10]. The mitochondrion is a complex organelle that,
depending on the tissue type, has variable functions in
cellular processes, such as controlling the oxidative state
of the cell [11,12]. In addition, the mitochondrion plays
an important role in energy production, predominantly
in vascularised aerobic tissues, as a generator of ATP.
The mitochondrion also regulates caspase-dependent
and caspase-independent apoptotic pathways [13]. The
classical signals for programmed cell death are preceded
by mitochondrial alterations, which include loss of mito-
chondrial membrane potential (ΔΨ), decrease in energy
production, increase in the permeability of the mitochon-
drial membrane, alteration of MRC activities, release of
pro-apoptotic factors, such as cytocrome c and downre-
gulation of antiapoptotic members, such as bcl-2 and
mcl-1, or activation of caspases pathways [14,15].
A variety of NO donors suppress the mitochondrial
respiration in different cell types, affecting energy pro-
duction [11,12]. Our study demonstrates that sodium
nitroprusside (SNP), a NO donor compound, reduces
activity of complex IV of the MRC of chondrocytes, caus-
ing apoptotic cell death [10,16]. Because synovial cells are
also affected in OA pathology, expressing high levels of
iNOs and producing high quantities of NO [17-19], and
because mitochondria may play a role in this highly vas-
cular aerobic tissue, we examined the effects of SNP on
synoviocyte survival relative to mitochondrial function.
Methods
Procurement, processing and culture of synoviocytes
Human OA synovia were obtained from patients under-
going hip joint replacement surgery at the Orthopaedic
Department of the Complejo Hospitalario Universitario
da Coruña. Human OA synovial explants were enzyma-
tically digested with 1.25 mg/ml bovine pancreas trypsin
(Roche Diagnostics, Mannheim, Germany) for one hour
with mixing at 37°C. The cells were then centrifuged
and resuspended in RPMI medium (BioWhittaker, Ver-
viers, Belgium) enriched with 20% fetal calf serum (FCS)
(Invitrogen, Carlsbad, CA, USA) and supplemented with
100 μl/ml glutamine (BioWhittaker), 100 μl/ml insulin-
transferrin-sodium selenite (Sigma-Aldrich, St Louis,
MO, USA). Culture was at 37°C in 5% CO2 in a
162 cm2 flask (Costar, Cambridge, MA, USA) for four
passages. After confluency was achieved, the cells were
made quiescent by incubation for 24 hours in RPMI
medium with 0.5% FCS before transfer to RPMI without
FCS for the experiments. For the experiments, the cells
were treated with the NO donor, SNP (Alexis Bio-
chemicals, San Diego, CA, USA) at 0.5, 1 or 2 mM for
varying times of incubation, or with valinomycin at 1
μM for the depolarization experiments (Sigma-Aldrich).
Controls were cultured under basal conditions, RPMI
only. This study was approved by the Ethics Committee
of Galicia-Spain.
Cell viability MTT assay
Cell viability (12 × 103 cells per well in a 96-well plate)
was evaluated using a colorimetric MTT assay measur-
ing reduction power (Roche Diagnostics). Following
incubation of cells for different time points under basal
conditions or with the experimental SNP concentrations,
soluble tetrazolium salt solution (10 μl at 5 mg/ml in
PBS) was added to the wells containing 100 μl of med-
ium and the plate was incubated for an additional
4 hours. 100 μl of 10% SDS in 0.01 M HCl solubilization
solution was then added to dissolve the water-insoluble
formazan salt. Quantification with a spectrophotometer
reader at 570 nm (GE Healthcare, Buckinghamshire,
UK) was conducted.
Determination of mitochondrial membrane potential
(Δψm)
To measure the Δψm of synoviocytes, DePsipher (R&D,
Abingdon, UK), a lipophilic cation (5,5’,6,6’-tetrachloro-
1,1’,3,3’-tetraethylbenzimidazolyl carbocyanide iodide)
was used. DePsipher exists as a monomer at low values
of Δψm (green fluorescence) and forms aggregates at
high Δψm (red fluorescence). Mitochondria with a nor-
mal Δψm concentrate DePsipher into aggregates (red
fluorescence), but with a de-energized or depolarized
Δψm, DePsipher forms monomers (green fluorescence).
For this procedure, synoviocytes were seeded at 25 ×
104 cells per well in 6-well plates in serum-free medium
(basal conditions) or treated with the different stimuli
for 12 hours. Valinomycin at 1 μM was utilized for the
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positive control. The synoviocytes collected by trypsini-
zation were then incubated with 1 μl/ml DePsipher for
20 minutes at 37°C in 5% CO2, sedimented, washed in
PBS and analyzed by flow cytometry using FACScan
(Becton Dickinson, Montain View, CA, USA) and Cell-
Quest software (Becton Dickinson). The analyzer thresh-
old was adjusted on the forward light scatter (FSC)
channel to exclude most subcellular debris. Photomulti-
plier settings were adjusted to detect green fluorescence
DePsipher monomer signals, centered at ~390 nm, on
the FL1 detector, and red fluorescence DePsipher aggre-
gate fluorescence signals, centered at ~340 nm, on the
FL2 detector. Mean fluorescence intensity values for
FL1 and FL2, expressed as arbitrary units, were obtained
for all experiments. In each experiment, at least 20,000
events were analyzed. The percentage of depolarization
in a cell population was calculated by dividing the values
of red fluorescence by the values of green fluorescence.
Measurement of synoviocyte ATP levels
To determine intracellular ATP levels, a luminescent
ATP detection assay system, based on the production of
light from the reaction of ATP with luciferase and
D-luciferin, was employed (Perkin Elmer, Barcelona,
Spain). Synoviocytes were seeded at 5 × 104 cells per
well in 96-well plates. Following incubation with or
without SNP at 0.5 mM, 50 μl per well of mammalian
cell lysis solution was added and the plate was shaken
for five minutes in an orbital shaker. 50 μl of a substrate
solution was then added and the microplate was shaken
for another five minutes. The plate was dark-adapted for
10 minutes, and the emitted light was measured by
luminometry in a Micro Beta TriLux (Perkin Elmer).
Measurement of MRC complex activities in digitonin-
permeabilized synoviocytes
Synoviocytes (3.5 × 106 per 140 mm diameter Petri dish)
were stimulated with SNP at 0.5 mM for 48 hours. Syno-
viocytes grown in basal medium served as controls. The
cells were collected by trypsinization, washed with phos-
phate buffered saline (PBS) and centrifuged at 150xg for
five minutes at 4°C. The pellet was resuspended in 2 ml
of ice-cold solution containing 20 mM MOPS, 0.25 M
sucrose and 200 μg of digitonin per 5 × 106 cells. After
five minutes incubation on ice, the suspension was cen-
trifuged at 5,000 × g for three minutes at 4°C. The result-
ing pellet was resuspended in 1.5 ml of 20 mM MOPS,
0.25 M sucrose and 1 mM of EDTA buffer, incubated for
five minutes and centrifuged at 10,000 × g for three min-
utes at 4°C. Finally, the pellet was resuspended in 200 μl
10 mM phosphate buffer (KP, pH 7.4), frozen and thawed
once, then mildly sonicated. These digitonin-permeabi-
lized homogenates were used to measure the activities of
respiratory chain enzymes and CS using a DU-650
spectrophotometer (Beckman Instruments, Palo Alto,
CA). Incubation temperatures were 30°C for rotenone-
sensitive NADH-coenzyme Q1 reductase (complex I),
succinate dehydrogenase (SDH; complex II), antimycin-
sensitive ubiquinol cytochrome c reductase (complex III)
and CS, and 38°C for cytochrome c oxidase (complex IV).
To correct for mitochondrial volume, enzyme activities
were normalized to the specific activity of CS. Complex I
was measured by the oxidation of NADH at 340 nm in
20 mM KP (pH 8.0), 200 μM NADH, 1 mM NaN3, 0.1%
bovine serum albumin (BSA)-EDTA, and 100 μM ubiqui-
none-1 (Sigma), first without rotenone (Calbiochem, La
Jolla, CA, USA), then with 5 μM rotenone added so a
rotenone-sensitive rate of NADH oxidation could be
calculated. Complex II (SDH) activity was assessed by the
reduction of 2,6-dichlorophenolindophenol (DCPIP)
(Sigma) at 600 nm in 50 mM Tris-KP (pH 7.0), 1.5 mM
KCN, 100 μM DCPIP, and 32 mM succinate (Sigma).
Complex III was assayed by measuring the reduction of
cytochrome c at 550 nm in 50 mM KP (pH 7.5), 2 mM
NaN3, 0.1% BSA-EDTA, 50 μM cytochrome c (Roche)
and 50 μM decyl-ubiquinol (Sigma), first without antimi-
cyn A (Sigma) and then with 0.01 mg/ml of antimycin A
added, so an antimicyn A-sensitive rate of cytochrome c
reduction could be calculated. Complex IV was measured
by the oxidation of reduced cytochrome c at 550 nm in
10 mM KP (pH 7.0) and 80 μM reduced cytochrome,
which was freshly prepared before each experiment by
adding sodium dithionite (Sigma). CS was evaluated at
420 nm in 75 mM Tris-HCl (pH 8), 100 μM 5,5’-dithio-
bis-(2-nitrobenzoic) acid (Sigma), 350 μg/ml acetyl-
coenzyme A (Sigma), 0.5 mM oxaloacetate (Roche
Diagnostics) and 0.1% Triton X-100 (Sigma).
Western blot
Cells (1.5 × 106 per 100 mm diameter Petri dish) were
incubated with SNP at 2 mM for 48 hours or in basal
conditions. After incubation, the cells were washed in
ice-cold PBS pH 7.5 and lysed in 0.2 M Tris-HCl pH
6.8 containing 2% SDS, 20% glycerol, 1 μg/ml cocktail
inhibitor and 1 mM phenyl methyl sulfonyl fluoride
(PMSF) (Sigma). Samples were boiled for 5 minutes and
protein concentrations were determined using the BCA
reagent assay (Pierce Chemical Co., Rockford, IL, USA).
Thirty μg of the protein extract were resolved on 12.5%
SDS-polyacrylamide gels, then transferred to polyvinyli-
dene difluoride membranes (Immobilon P, Millipore
Co., Bedford, MA, USA). These membranes were first
blocked in Tris buffered saline (TBS) pH 7.4, containing
0.1% Tween-20 (Invitrogen) and 5% nonfat dried milk
for 60 minutes at room temperature, then incubated
overnight with mouse anti-human bcl-2 1:2000 (R&D),
mouse anti-human mcl-1 1:500 (Oncogene, Cambridge
MA, US) or mouse anti-human caspase 3 1:2000 (R&D)
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in fresh blocking solution at 4°C. After washing, the
membranes were incubated with peroxidase conjugated
secondary antibodies, developed using the ECL chemilu-
minescence kit (GE Healthcare) and digitized using LAS
3000 image analyzer. Quantitative changes in band
intensities were evaluated using ImageQuant 5.2 soft-
ware (GE Healthcare). Densitometric values for the
Western blot bands containing the protein of interest
were normalized against those of a-tubulin (Sigma)
obtained from the same sample.
Statistical analyses
The data are expressed as the mean ± SE from the
determinations as described. Individual donors were stu-
died in duplicate; pooled cells from different donors
were not used in any experiment. The statistical soft-
ware program, SPSS (version 15.0, SPSS, Chicago, IL,
USA) was used to perform the analysis of variance
(ANOVA) and Tukey tests. Differences were considered
to be statistically significant at p ≤ 0.05.
Results
Effect of NO on synoviocyte viability
Analyses of viability using MTT assay methods to measure
the cellular reduction power showed that the NO donor,
SNP, reduced synoviocyte viability with a time-dependent
decrease in the percentages (figure 1). At 24, 48 and 72
hours of incubation, respectively: SNP at 0.5 mM: 86.11 ±
4.9%, 74.31 ± 3.35%, 43.88 ± 1.43% vs. 100% basal; SNP at
1 mM: 85.52 ± 5.91%, 11.91 ± 0.72%, 7.1 ± 0.41% vs. 100%
basal; and SNP at 2 mM: 77.85 ± 6.46%, 15 ± 0.52%, 10.85
± 0.56% vs. basal 100%, ([n = 8]; *p < 0.05).
Effect of SNP on mitochondria
A second set of experiments examined the effects of SNP
on mitochondrial function by determining the Δψm, ATP
synthesis and activities of the respiratory chain complexes
I-IV and CS. To assess the effect of SNP on the Δψm of
synoviocytes, the fluoresecent probe DePsipher was used.
The staining pattern of DePsipher for basal synoviocytes
was established as the standard. The total cell population
was divided into two subsets: one with normal Δψm (red
fluorescence or high levels of FL-2), as the left upper
panels represent in figure 2A, and another with lower
Δψm (green fluorescence or high levels of FL-1), as the
right lower panels represent in figure 2A. The treatment
of synoviocytes with SNP at 0.5 mM for 12 hours reduced
the percentage of cells with normal mitochondrial polari-
zation [basal: 48.08 ± 3.59%; SNP at 0.5 mM: 36.04 ±
2.77%; and valinomycin at 1 μM: 17.04 ± 2.38% (n = 8,
*p < 0.01)] (Figure 2A) and increased the number of cells
with mitochondrial depolarization [basal: 6.76 ± 2.14%;
SNP at 0.5 mM: 9.96 ± 1.45%; and valinomycin at 1 μM:
26.87 ± 2.92%, (n = 8, *p < 0.01)] (Figure 2A). SNP treat-
ment at 0.5 mM caused a significant decrease in the red/
green fluorescence ratio (basal: 2.48 ± 0.28; SNP at
0.5 mM: 1.57 ± 0.11; and valinomycin at 1 μM: 0.93 ±
0.06, (n = 8, *p < 0.01)] (figure 2B).
We also assessed the effects of SNP on ATP produc-
tion. Treatment with SNP at 0.5 mM for 6, 24, 48 and 72
hours significantly decreased ATP production [6 hours:
68.34 ± 14.3%; 24 hours: 75.04 ± 13.32%; 48 hours: 75.28
± 12.94%; and 72 hours: 75.54 ± 16.3%, compared to the
basal value of 100%, (n = 8) *p < 0.05)] (figure 3). These
results indicate that SNP affects mitochondrial function,
therefore, we evaluated the MRC activity of human OA
synoviocytes treated with SNP at 0.5 mM for 48 hours.
Figure 4 shows that the NO donor induced an increase in
activity of complex I (basal: 36.47 ± 3.92 mol/min/mg
prot.; SNP at 0.5 mM: 58.08 ± 6.46 mol/min/mg prot.)
and of complex III (basal: 63.87 ± 6.93 mol/min/mg
prot.; SNP at 0.5 mM: 109.15 ± 30.37 mol/min/mg prot.),
(n = 6, *p < 0.05). However, SNP at 0.5 mM produced a
decrease in the activity of CS [basal: 105.06 ± 10.72 mol/
min/mg prot.; SNP at 0.5 mM: 66.88 ± 6.08 mol/min/mg
prot., (n = 6, *p < 0.05)], which indicates a reduction in
mitochondrial mass.
Effect of SNP on cell cycle protein expression
Mitochondria are one of the initiators of apoptosis and
regulate the cell cycle because they modulate the activity
of anti- or pro-apoptotic elements, such as bcl-2 and the
caspase family. To define the proteins implicated in SNP
mitochondrial regulation and in induced death, we stu-
died the expression pattern of bcl-2 and mcl-1 anti-
apoptotic proteins, as well as the pro-apoptotic caspase
3. We observed that levels of bcl-2 protein in OA
Figure 1 Effect of sodium nitroprusside (SNP) on the cell
viability of human osteoarthritic (OA) synoviocytes. Human OA
synoviocytes were incubated under basal conditions (RPMI only) or
with SNP at concentrations of 0.5, 1 and 2 mM for 24, 48 and 72
hours. Cell viability was evaluated using a colorimetric analysis
based on the MTT assay as detailed in the Methods section. The
data are expressed as percentages of those of the control
conditions (100%), and represent the mean ± standard error of
eight different experiments performed in duplicate (*p < 0.05).
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synoviocytes were downregulated by treatment with 2
mM SNP at 48 h [(47.75 ± 18.93% vs. basal 100%, (n =
4; *p < 0.05)] (figure 5A), as well those of mcl-1 [48.67
± 15.00% vs. basal 100%, (n = 3; *p < 0.05] (figure 5B).
We also found a decrease in the inactive proform of cas-
pase 3 detected after treatment with SNP at 2 mM for
48 hours [66.02 ± 8.64 vs. basal 100%, (n = 3); *p <
0.05) (figure 5C)]. A representative experiment of each
analysis is shown in figure 5D.
Discussion
In OA pathology, the process leading to an aberrant car-
tilage structure characterized by reduction in the num-
ber of chondrocytes, loss of extracellular matrix,
synovial inflammation, and irregular proliferation and
death of synoviocytes is time- or age-dependent [20-22].
The pathogenesis of OA includes increased NO levels
by chondrocytes and synovial cells as a consequence of
the up-regulation of NO synthase (NOS) induced by IL-
1b, TNF-a and other factors [23]. The role of NOS has
been of interest in the pathogenesis of OA because of
its role in the induction of chondrocyte and synoviocyte
death [10]. Our earlier study established that the NO
donor, SNP, induced an increase in hypodiploid DNA of
human chondrocytes. It also induced mRNA expression
of caspase-7 and reduced the expression of mRNA and
protein synthesis of bcl-2 by human chondrocytes [10].
Further, SNP reduced chondrocyte survival and induced
Figure 2 Measurement of mitochondrial membrane depolarization following sodium nitroprusside (SNP) treatment of human
osteoarthritic (OA) synoviocytes. A) Cells were incubated for 12 hours in medium alone (control), with 0.5 mM SNP, or with 1 μM valinomycin
(positive control). The mitochondrial membrane potential was determined by flow cytometry using DePsipher. Data acquisition was performed
using a FACScan flow cytometer as detailed in the Methods section. A representative density plot for each treatment group is shown. The
numbers represent the percentage of the mean ± standard error of each population from eight different experiments performed in duplicate
(*p < 0.01). B) Histograms represent DePsipher fluorescence of SNP-stimulated synoviocytes. Relative to the control, green fluorescence (light
line) increases while red fluorescence (dark line) decreases in SNP- or valinomycin-stimulated synoviocytes. The numbers represent the mean ±
standard error of red/green fluorescence ratio values of eight different experiments performed in duplicate (*p < 0.01).
Cillero-Pastor et al. BMC Musculoskeletal Disorders 2011, 12:42
http://www.biomedcentral.com/1471-2474/12/42
Page 5 of 9
cell death with morphologic changes characteristic of
chondrocyte apoptosis.
Mitochondria are important organelles in most cells
and, particularly, in aerobic tissues, such as the synovial
membrane. Pertaining to the importance of mitochon-
dria in OA pathology, Rego et al. found that some hap-
logroups of mitochondrial respiratory genes of
chondrocytes confer increased predisposition to the
development of OA [24]. Also, the activity of the mito-
chondrial complexes II and III is lower in OA than in nor-
mal human chondrocytes. This produces a decrease in
ATP levels as well as a higher reactive oxygen species
(ROS) generation [25,26]. Mitochondrial complex inhibi-
tors, such as antimycin A and oligomycin, induce ROS
production, NF-B activation, COX expression and PGE2
production in chondrocytes in culture [27]. In rabbit and
human chondrocytes, SNP suppresses mitochondrial
respiration by reducing oxygen consumption and by
diminishing ATP levels [25,28]. In human chondrocytes,
SNP decreased the Δψm as measured by the ratio of red/
green fluorescence of DePsipher and inhibited the activity
of complex IV of the MRC [10]. Regulation of the MRC
may be a signalling pathway by which NO modulates
articular cartilage matrix biosynthesis and pathologic
mineralization. There are no previous studies of mito-
chondrial integrity in relation to the energy production in
synoviocytes, although some mtDNA somatic mutations
and the importance of normal Δψm have been studied
[29,19]. Because the synovial membrane is an aerobic tis-
sue, we speculated that mitochondrial integrity is neces-
sary for synoviocyte survival. Studies have shown that
proteins that are clearly regulated by mitochondria, such
as the bcl-2 family, regulate the viability of synoviocytes
[30]. Previous studies also found that NO induced syno-
viocyte death by regulating the expression of the protein
p53 and the activation of caspase 3, although we found no
publications concerning the importance of the MRC in
synoviocyte ATP production [31,32,19]. For these reasons,
we set out to study the effects of NO in relation to mito-
chondrial function in human OA synoviocytes. In our
study, the NO donor SNP was able to reduce the survival
of synoviocytes, as expected. We observed that SNP
increased the hypodiploid cell number (data not shown),
similar to an apoptotic or similar programmed cell death,
as other authors have elucidated [19,31]. We thought that
this decrease in cell viability might be due in part to the
effect of NO on mitochondrial function. From our results,
we have concluded that SNP depolarized Δψm and, as a
probable consequence of irregular electron distribution
along this membrane, we found a reduction in ATP pro-
duction. However, the activities of the MRC complexes I
and III were increased, possibly due to an adaptive effort
by damaged synovial cells to produce more energy. We
also found a decrease in CS activity, indicating a reduction
in the mitochondria mass following SNP treatment, prob-
ably causing the ATP depletion. Apart from mitochondrial
dysfunction, another explanation for the lowered ATP
Figure 3 ATP production of synoviocytes stimulated with
sodium nitroprusside (SNP). Synoviocytes were cultured in basal
conditions (only RPMI) or treated with SNP at 0.5 mM for 6, 24, 48
and 72 hours and collected for whole cell ATP measurement as
described in the Methods section. ATP values are expressed as the
mean ± standard error of eight different experiments performed in
duplicate (*p < 0.05).
Figure 4 Activity of mitochondrial respiratory chain (MRC)
complexes of osteoarthritic (OA) synoviocytes incubated with
sodium nitroprusside (SNP). A) Confluent synoviocytes were
incubated for 48 hours under basal conditions (RPMI only) or with
SNP at 0.5 mM and MRC complex activities were measured as
reported in Methods. Citrate synthase (CS)-corrected complex
activity is expressed as nmol/min/mg protein/CS specific activity
x100. Complex I = rotenone-sensitive NADH-coenzyme Q1
reductase; Complex II = succinate dehydrogenase; Complex III =
antimycin-sensitive ubiuqinol cytocrome c reductase; Complex IV =
cytocrome c oxidase. The values are the mean ± standard error of
six experiments performed in duplicate (*p < 0.05). B) The activity of
CS following stimulation with SNP at 0.5 mM was evaluated. The
values are the mean ± standard error of six experiments performed
in duplicate (*p < 0.05).
Cillero-Pastor et al. BMC Musculoskeletal Disorders 2011, 12:42
http://www.biomedcentral.com/1471-2474/12/42
Page 6 of 9
levels could be that SNP reduces the expression of
G3PDH protein, an important enzyme in glucose metabo-
lism in OA synoviocytes [33]. It appears that SNP binds to
glucose receptors irreversibly [33], impacting the glycolytic
pathway and generation of energy. The low levels of ATP
explain why the synoviocytes die. We also were able to
show that the mcl-1 and bcl-2 anti-apoptotic proteins
were downregulated in the presence of SNP after 48 hours
of treatment, helping to explain the programmed cell
death NO induces [34]. Another study has shown that
mcl-1 has an important role in neuron survival before and
after damage to DNA [35]. The full length of caspase 3
was also decreased, probably because it was transformed
to the smaller activated state, as other investigators have
shown [19]. Direct investigation of the functions of NO
production by chondrocytes has been hampered by the
lack of uniformity existing among different types of NO
donor compounds employed in the experiments [36]. The
majority of studies have used SNP for the NO donor
compound, and results show that it reduces cell survival
and induces cell death with the morphologic changes
characteristic of apoptosis [10,19]. A second possible
explanation for the finding that NO reduced cell survival
in all these cell types may lie in the interaction of addi-
tional reactive oxygen species (ROS), possibly concomi-
tantly produced as a consequence of NO itself [19]. Also,
an increase in intracellular levels of ROS from increased
activity of MRC complexes I and III provides a condition
where the intracellular redox status of the cell could be
altered [37,38]. In this case, the action of NO on Δψm
would increase the production of ROS by mitochondria
and also the cytotoxicity associated with NO and some
reactive nitrogen species (RNS), such as peroxynitrite [19].
A recent study on peroxynitrite mediated-chondrocyte
apoptosis found that the predominant mode of cell death
involved calcium-dependent cysteine proteases, known as
calpains, and that peroxynitrite induced mitochondrial
dysfunction in cells leading to caspase-independent
Figure 5 Protein expression of apoptotic factors. The expression of pro- and anti-apoptotic proteins was studied in synoviocytes treated with
SNP at 2 mM for 48 hours. Cell protein lysates were subjected to western blot analysis. a-tubulin was used to standardize the total protein charged
and expressions of bcl-2 (A) mcl-1 (B) and pro-caspase 3 (C) were evaluated. D) A representative experiment is shown. The results are shown as
percentage of non-treated control cells (100%). Values are expressed as the mean ± standard error of three independent experiments (*p < 0.05).
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apoptosis [39]. This hypothetical elevation of ROS and
RNS production can form nitrotyrosine complexes with
other proteins, increasing and amplifiying the effects that
NO alone has as shown in joint tissues from OA and RA
patients [40-42].
Conclusions
In this study we demonstrated and elucidated the impor-
tant role that NO has in mitochondrial integrity, in energy
production and in regulation of the survival of synovio-
cytes. This information helps us understand the role of
mitochondria in the development of OA pathology.
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